Metabolic syndrome: a work in progress, but a useful construct.
Beaser
Richard S
RS
Joslin Diabetes Center and Harvard Medical School, Boston, MA 02215, USA. Richard.beaser@joslin.harvard.edu
Levy
Philip
P
D050153:Abdominal Fat / Q000503:physiopathology; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D015331:Cohort Studies; D003327:Coronary Disease / Q000209:etiology; D003924:Diabetes Mellitus, Type 2 / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D006973:Hypertension / Q000150:complications; D007333:Insulin Resistance; D024821:Metabolic Syndrome / Q000150:complications / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy; D008954:Models, Biological; D009765:Obesity / Q000150:complications / Q000503:physiopathology; D011379:Prognosis; D012307:Risk Factors; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use
D000806:Angiotensin-Converting Enzyme Inhibitors; D045162:Thiazolidinediones; D000077154:Rosiglitazone